This Government Contract opportunity from Department Of Health And Human Services was posted on September 14, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The National Institutes of Health Office of the Director intends to award a firm-fixed-price purchase order to the University of Illinois at Chicago for preclinical animal research services. The project focuses on evaluating the therapeutic effects of soluble adenylyl cyclase inhibition on pulmonary arterial hypertension using an established endothelial cell-specific Cav1 knockout murine model and wild-type controls. The University of Illinois at Chicago is identified as the sole source for this requirement because it maintains the specific mouse colony necessary for the study, which is not known to be available from other laboratories. The anticipated period of performance is 12 months from the date of award, and the total cost is not expected to exceed the simplified acquisition threshold. The scope of work includes the breeding, colony maintenance, and genotyping of 144 animals, as well as performing euthanasia, necropsy, and the collection of lung and heart tissue for histological analysis, Western blotting, and RNA-seq. Additionally, the contractor will prepare serum and plasma samples for government analysis. The government will provide 200 mg each of KH7 and LRE1 compounds, delivered directly from the manufacturer. While the government intends to negotiate on a sole-source basis pursuant to FAR 13.106-1(b)(1), other responsible sources may submit capability statements and quotations by September 21, 2026, to demonstrate their technical capability and availability of the required animal model.
General Info
Place of Performance
Chicago, IL, 60607, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The National Institutes of Health (NIH) intends to negotiate on a sole-source basis with the University of Illinois at Chicago (UIC) for preclinical animal research services to evaluate the therapeutic effects of soluble adenylyl cyclase (sAC) inhibition on pulmonary arterial hypertension (PAH) using an established endothelial cell-specific Cav1 knockout (EC-Cav1 KO) murine model and corresponding wild-type controls.
The Government intends to solicit from a single source pursuant to FAR 13.106-1(b)(1). UIC currently maintains the established EC-Cav1 KO mouse colony required for this study, and the model is not known to be maintained by another laboratory.
This notice of intent is not a request for competitive quotations. However, all responsible sources that believe they can satisfy the Government's requirements may submit a capability statement and/or quotation for consideration by the Government.
Please see the attached Notice of Intent to Sole Source for the complete description of the requirement, basis for the intended sole-source acquisition, response instructions, and applicable response deadline.
More opportunities from Department Of Health And Human Services → National Institute Of Health Nih-Od
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
